WO2005030186A2 - Method for attenuating virulence of microbial pathogens and for inhibiting microbial biofilm formation - Google Patents

Method for attenuating virulence of microbial pathogens and for inhibiting microbial biofilm formation Download PDF

Info

Publication number
WO2005030186A2
WO2005030186A2 PCT/US2004/023498 US2004023498W WO2005030186A2 WO 2005030186 A2 WO2005030186 A2 WO 2005030186A2 US 2004023498 W US2004023498 W US 2004023498W WO 2005030186 A2 WO2005030186 A2 WO 2005030186A2
Authority
WO
WIPO (PCT)
Prior art keywords
gmp
biofilm
microbial
aureus
colonization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/023498
Other languages
English (en)
French (fr)
Other versions
WO2005030186A3 (en
Inventor
David K. R. Karaolis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Maryland Baltimore
University of Maryland College Park
Original Assignee
University of Maryland Baltimore
University of Maryland College Park
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Maryland Baltimore, University of Maryland College Park filed Critical University of Maryland Baltimore
Priority to EP04809506A priority Critical patent/EP1651242A2/en
Priority to AU2004275696A priority patent/AU2004275696B2/en
Priority to US10/565,591 priority patent/US8367716B2/en
Priority to CA002533873A priority patent/CA2533873A1/en
Priority to JP2006521912A priority patent/JP2007500697A/ja
Publication of WO2005030186A2 publication Critical patent/WO2005030186A2/en
Publication of WO2005030186A3 publication Critical patent/WO2005030186A3/en
Priority to IL173065A priority patent/IL173065A/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • Clostridium. spp. Rhodococcus spp. , Thermatoga spp. , Sphingomonas spp. , Zymomonas spp. , Micrococcus spp. , Azotobacter spp. , Norcardia spp. , Brevibacterium spp. , Alcaligenes spp. , Microbispora spp. , Micromonospora spp.
  • Agrobacterium tumefaciens Staphylococcus aureus, Staphylococcus epidennidis, Staphylococcus hominis, Staphylococcus . haemolyticus, Staphylococcus warneri, Staphylococcus cohnii, Staphylococcus saprophyticus , Staphylococcus capitis, Staphylococcus lugdunensis, Staphylococcus inte edius, Staphylococcus hyicus, Staphylococcus saccharolyticus and Rhizobium. spp . , and mutants thereof.
  • compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
  • the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen free water, before use.
  • the compositions may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa, butter or other glycerides .
  • Vibrio cholerae can switch to a "rugose" phenotype characterized by an exopolysaccharide (EPS) matrix, wrinkled colony morphology, increased biofilm formation and increased survival under specific conditions.
  • EPS exopolysaccharide
  • rEPS rugose EPS
  • VpsR VpsR
  • Media (APW#3) promoting EPS production and the rugose phenotype was identified and epidemic strains were found to switch at higher frequency than nonpathogenic strains, suggesting this switch and extracellular polysaccharide is important in cholera epidemiology.
  • transposon mutagenesis on a smooth V.
  • cholerae AmiB is also predicted to contain a LysM (lysin motif) domain at its C- ter inal end and this has been found in enzymes involved in cell wall degradation (Bateman et al . , 2000). Interestingly, the V. cholerae AmiB contains a Arg-Gly-Asp (RGD) motif that is often associated with a surface binding domain for various mammalian adhesion proteins.
  • RGD Arg-Gly-Asp
  • Cyclic di-guanosine-monophosphate comes of age: a novel secondary messenger involved in modulating cell surface structures in bacteria? Curr Opin Microbiol. 7:185- 91.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
PCT/US2004/023498 2003-07-28 2004-07-22 Method for attenuating virulence of microbial pathogens and for inhibiting microbial biofilm formation Ceased WO2005030186A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP04809506A EP1651242A2 (en) 2003-07-28 2004-07-22 Method for attenuating virulence of microbial pathogens and for inhibiting microbial biofilm formation
AU2004275696A AU2004275696B2 (en) 2003-07-28 2004-07-22 Method for attenuating virulence of microbial pathogens and for inhibiting microbial biofilm formation
US10/565,591 US8367716B2 (en) 2003-07-28 2004-07-22 Method for attentuating virulence of microbial pathogens and for inhibiting microbial biofilm formation
CA002533873A CA2533873A1 (en) 2003-07-28 2004-07-22 Method for attenuating virulence of microbial pathogens and for inhibiting microbial biofilm formation
JP2006521912A JP2007500697A (ja) 2003-07-28 2004-07-22 微生物病原体の毒性を減弱させる方法、および微生物のバイオフィルム形成を阻害する方法
IL173065A IL173065A (en) 2003-07-28 2006-01-10 USE OF c-dI-GMP OR A CYCLIC DINUCLEOTIDE ANALOGUE THEREOF IN THE MANUFACTURE OF A MEDICAMENT,

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49002903P 2003-07-28 2003-07-28
US60/490,029 2003-07-28

Publications (2)

Publication Number Publication Date
WO2005030186A2 true WO2005030186A2 (en) 2005-04-07
WO2005030186A3 WO2005030186A3 (en) 2005-07-14

Family

ID=34392905

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/023498 Ceased WO2005030186A2 (en) 2003-07-28 2004-07-22 Method for attenuating virulence of microbial pathogens and for inhibiting microbial biofilm formation

Country Status (7)

Country Link
US (1) US8367716B2 (enExample)
EP (1) EP1651242A2 (enExample)
JP (1) JP2007500697A (enExample)
AU (1) AU2004275696B2 (enExample)
CA (1) CA2533873A1 (enExample)
IL (1) IL173065A (enExample)
WO (1) WO2005030186A2 (enExample)

Cited By (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005089777A1 (en) * 2004-03-15 2005-09-29 Karaolis David K R A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis
EP1782826A1 (en) * 2005-11-08 2007-05-09 GBF Gesellschaft für Biotechnologische Forschung mbH PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions
WO2009133560A1 (en) * 2008-04-29 2009-11-05 Smart Assays Non-hydrolyzable and permeable cyclic bis-[nucleotide monophosphate] derivatives and uses thereof
CN101843899A (zh) * 2010-05-24 2010-09-29 中国人民解放军第三军医大学 耐甲氧西林金黄色葡萄球菌（mrsa）重组多亚单位基因工程疫苗及其制备方法
WO2011003025A1 (en) * 2009-07-01 2011-01-06 Rutgers, The State University Of New Jersey Synthesis of cyclic diguanosine monophosphate and thiophosphate analogs thereof
CN102199183A (zh) * 2010-03-26 2011-09-28 北京大学 环二鸟苷酸及其类似物和制备方法
WO2012021554A1 (en) * 2010-08-09 2012-02-16 Yale University Cyclic di-gmp-ii riboswitches, motifs, and compounds, and methods for their use
US8343536B2 (en) 2007-01-25 2013-01-01 Cook Biotech Incorporated Biofilm-inhibiting medical products
US8450293B2 (en) 2010-08-10 2013-05-28 Rutgers, The State University Of New Jersey Synthesis and characterization of C8 analogs of c-di-GMP
CN104152472A (zh) * 2012-12-28 2014-11-19 陶飞 一种双鸟苷酸环化酶基因、载体、工程菌及其应用
US9315523B2 (en) 2013-12-06 2016-04-19 Rutgers, The State University Of New Jersey Cyclic dinucleosides
EP2996472A4 (en) * 2013-05-18 2016-12-28 Aduro Biotech Inc COMPOSITIONS AND METHODS FOR INHIBITING DEPENDENT SIGNALING OF "INTERFERON GENE STIMULATOR"
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
US9695212B2 (en) 2012-12-13 2017-07-04 Aduro Biotech, Inc. Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
US9724408B2 (en) 2013-05-18 2017-08-08 Aduro Biotech, Inc. Compositions and methods for activating stimulator of interferon gene-dependent signalling
US9770467B2 (en) 2012-06-08 2017-09-26 Aduro Biotech, Inc. Compositions and methods for cancer immunotherapy
US9840533B2 (en) 2013-04-29 2017-12-12 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
US10176292B2 (en) 2013-07-31 2019-01-08 Memorial Sloan-Kettering Cancer Center STING crystals and modulators
WO2019043634A2 (en) 2017-08-30 2019-03-07 Beijing Xuanyi Pharmasciences Co., Ltd. CYCLIC DI-NUCLEOTIDES AS STIMULATORS OF INTERFERON GENE MODULATORS
US10336786B2 (en) 2012-12-19 2019-07-02 Board Of Regents, The University Of Texas System Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
US10519188B2 (en) 2016-03-18 2019-12-31 Immunesensor Therapeutics, Inc. Cyclic di-nucleotide compounds and methods of use
US11787833B2 (en) 2019-05-09 2023-10-17 Aligos Therapeutics, Inc. Modified cyclic dinucleoside compounds as sting modulators
US11873319B2 (en) 2013-05-03 2024-01-16 The Regents Of The University Of California Cyclic di-nucleotide induction of type I interferon

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006073514A2 (en) * 2004-08-25 2006-07-13 Tufts University Compositions, methods and kits for repressing virulence in gram positive bacteria
BRPI0811530B1 (pt) 2007-05-14 2019-01-02 Research Foundation Of State Univ Of New York composição compreendendo indutor(es) de resposta fisiológica à dispersão ácido decanóico, superfície, solução, método ex vivo de tratamento ou inibição da formação de um biofilme sobre uma superfície
EP2254591B1 (en) 2008-02-08 2017-07-26 Prothera, Inc. Inhibition and treatment of gastrointestinal biofilms
JP6153116B2 (ja) * 2013-01-09 2017-06-28 国立大学法人東北大学 トリアゾール連結型環状ジヌクレオチド類縁体
ES2692226T3 (es) 2014-06-04 2018-11-30 Glaxosmithkline Intellectual Property Development Limited Dinucleótidos cíclicos como moduladores de STING
GB201501462D0 (en) 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
HK1247089A1 (zh) 2015-03-10 2018-09-21 Aduro Biotech, Inc. 用於活化“干扰素基因刺激物”依赖性信号传导的组合物和方法
MX363780B (es) 2015-12-03 2019-04-03 Glaxosmithkline Ip Dev Ltd Dinucleótidos de purina cíclica como moduladores del estimulador de los genes de interferón.
US11098077B2 (en) 2016-07-05 2021-08-24 Chinook Therapeutics, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
JOP20170192A1 (ar) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
PE20210156A1 (es) 2017-11-10 2021-01-26 Takeda Pharmaceuticals Co Compuestos moduladores de sting y metodos de elaboracion y uso
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance
WO2020031083A1 (en) * 2018-08-06 2020-02-13 KHAN, Khalid Antimicrobial formulations comprising vancomycin or tobramycin
CN114085887A (zh) * 2020-08-25 2022-02-25 中国科学院大连化学物理研究所 一种基于仿生微球的铜绿假单胞菌耐药浓度的检测方法
EP4240488A1 (en) 2020-11-09 2023-09-13 Takeda Pharmaceutical Company Limited Antibody drug conjugates
CN114099657B (zh) * 2021-11-04 2022-05-17 暨南大学 一种溶藻弧菌减毒活疫苗及其制备方法与应用
KR102551061B1 (ko) * 2022-05-26 2023-07-03 중앙대학교 산학협력단 Saha를 유효성분으로 포함하는 살모넬라 속 균주에 의한 바이오필름 생성 저해용 조성물
CN118956719B (zh) * 2024-07-31 2025-05-09 武汉市仪泰环境科技有限公司 一种毒性检测中加快微生物挂膜的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268274A (en) * 1989-04-12 1993-12-07 Cetus Corporation Methods and nucleic acid sequences for the expression of the cellulose synthase operon
AU1672492A (en) * 1991-05-03 1992-12-21 University Technologies International Inc. Biofilm reduction method
GB2257704B (en) 1991-07-18 1995-03-01 Erba Carlo Spa Cyclic oligonucleotides phosphorothioates
US20020091074A1 (en) * 2000-09-20 2002-07-11 Wooley Richard E. Medical compositions, dressings and methods for treating microbial infections of skin lesions
US20020169288A1 (en) * 2001-03-15 2002-11-14 Magnus Hook Collagen-binding adhesin from staphylococcus epidermidis and method of use
JP2002302404A (ja) * 2001-04-02 2002-10-18 Shiseido Co Ltd 抗菌防黴助剤
US7189351B2 (en) * 2001-10-25 2007-03-13 Spherix Incorporated D-tagatose as an anti-biofilm agent

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GALPERIN MICHAEL Y ET AL: "Novel domains of the prokaryotic two-component signal transduction systems" FEMS MICROBIOLOGY LETTERS, vol. 203, no. 1, 11 September 2001 (2001-09-11), pages 11-21, XP002322854 ISSN: 0378-1097 cited in the application *
JENAL URS: "Cyclic di-guanosine-monophosphate comes of age: a novel secondary messenger involved in modulating cell surface structures in bacteria?" CURRENT OPINION IN MICROBIOLOGY, vol. 7, no. 2, 2 March 2004 (2004-03-02), pages 185-191, XP002322847 ISSN: 1369-5274 cited in the application *
RASHID MOHAMMED H ET AL: "Identification of genes involved in the switch between the smooth and rugose phenotypes of Vibrio cholerae." FEMS MICROBIOLOGY LETTERS, vol. 227, no. 1, 6 September 2003 (2003-09-06), pages 113-119, XP002322846 ISSN: 0378-1097 *

Cited By (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005087238A3 (en) * 2004-03-15 2006-03-09 David K R Karaolis Method for stimulating the immune, inflammatory or neuroprotective response
US7569555B2 (en) 2004-03-15 2009-08-04 Karaolis David K R Method for stimulating the immune, inflammatory or neuroprotective response
US7709458B2 (en) 2004-03-15 2010-05-04 David K. R. Karaolis Method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis
AU2005221717B2 (en) * 2004-03-15 2010-08-05 Karagen Pharmaceuticals, Inc. Method for stimulating the immune, inflammatory or neuroprotective response
WO2005089777A1 (en) * 2004-03-15 2005-09-29 Karaolis David K R A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis
EP1782826A1 (en) * 2005-11-08 2007-05-09 GBF Gesellschaft für Biotechnologische Forschung mbH PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions
WO2007054279A3 (en) * 2005-11-08 2007-08-30 Helmholtz Infektionsforschung Cyclic-dinucleotides and its conjugates as adjuvants and their uses in pharmaceutical compositions
AU2006312688B2 (en) * 2005-11-08 2013-05-16 Helmholtz-Zentrum Fur Infektionsforschung Gmbh Cyclic-dinucleotides and its conjugates as adjuvants and their uses in pharmaceutical compositions
US8343536B2 (en) 2007-01-25 2013-01-01 Cook Biotech Incorporated Biofilm-inhibiting medical products
WO2009133560A1 (en) * 2008-04-29 2009-11-05 Smart Assays Non-hydrolyzable and permeable cyclic bis-[nucleotide monophosphate] derivatives and uses thereof
US20120178710A1 (en) * 2009-07-01 2012-07-12 Rutgers, The State University Of New Jersey Synthesis of cyclic diguanosine monophosphate and thiophosphate analogs thereof
WO2011003025A1 (en) * 2009-07-01 2011-01-06 Rutgers, The State University Of New Jersey Synthesis of cyclic diguanosine monophosphate and thiophosphate analogs thereof
CN102199183A (zh) * 2010-03-26 2011-09-28 北京大学 环二鸟苷酸及其类似物和制备方法
CN102199183B (zh) * 2010-03-26 2013-12-18 北京大学 环二鸟苷酸及其类似物和制备方法
CN101843899A (zh) * 2010-05-24 2010-09-29 中国人民解放军第三军医大学 耐甲氧西林金黄色葡萄球菌（mrsa）重组多亚单位基因工程疫苗及其制备方法
WO2012021554A1 (en) * 2010-08-09 2012-02-16 Yale University Cyclic di-gmp-ii riboswitches, motifs, and compounds, and methods for their use
US8450293B2 (en) 2010-08-10 2013-05-28 Rutgers, The State University Of New Jersey Synthesis and characterization of C8 analogs of c-di-GMP
US9770467B2 (en) 2012-06-08 2017-09-26 Aduro Biotech, Inc. Compositions and methods for cancer immunotherapy
US10414789B2 (en) 2012-12-13 2019-09-17 Aduro Biotech, Inc. Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
US9695212B2 (en) 2012-12-13 2017-07-04 Aduro Biotech, Inc. Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
US10633411B2 (en) 2012-12-19 2020-04-28 The Board Of Regents Of The University Of Texas System Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
US10696710B2 (en) 2012-12-19 2020-06-30 The Board Of Regents Of The University Of Texas System Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
US10508129B2 (en) 2012-12-19 2019-12-17 The Board Of Regents Of The University Of Texas System Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
US11492368B2 (en) 2012-12-19 2022-11-08 The Board Of Regents Of The University Of Texas System Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
US10336786B2 (en) 2012-12-19 2019-07-02 Board Of Regents, The University Of Texas System Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
CN104152472A (zh) * 2012-12-28 2014-11-19 陶飞 一种双鸟苷酸环化酶基因、载体、工程菌及其应用
US10385091B2 (en) 2013-04-29 2019-08-20 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
US9840533B2 (en) 2013-04-29 2017-12-12 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
US11014956B2 (en) 2013-04-29 2021-05-25 Memorial Sloan Kettering Cancer Center; The Rockefeller Compositions and methods for altering second messenger signaling
US10131686B2 (en) 2013-04-29 2018-11-20 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
US11873319B2 (en) 2013-05-03 2024-01-16 The Regents Of The University Of California Cyclic di-nucleotide induction of type I interferon
US10653774B2 (en) 2013-05-18 2020-05-19 Aduro Biotech, Inc. Compositions and methods for activating “stimulator of interferon gene”-dependent signalling
US9724408B2 (en) 2013-05-18 2017-08-08 Aduro Biotech, Inc. Compositions and methods for activating stimulator of interferon gene-dependent signalling
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
US10189873B2 (en) 2013-05-18 2019-01-29 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”-dependent signalling
EP2996472A4 (en) * 2013-05-18 2016-12-28 Aduro Biotech Inc COMPOSITIONS AND METHODS FOR INHIBITING DEPENDENT SIGNALING OF "INTERFERON GENE STIMULATOR"
US10176292B2 (en) 2013-07-31 2019-01-08 Memorial Sloan-Kettering Cancer Center STING crystals and modulators
US9315523B2 (en) 2013-12-06 2016-04-19 Rutgers, The State University Of New Jersey Cyclic dinucleosides
US10519188B2 (en) 2016-03-18 2019-12-31 Immunesensor Therapeutics, Inc. Cyclic di-nucleotide compounds and methods of use
US11299512B2 (en) 2016-03-18 2022-04-12 Immunesensor Therapeutics, Inc. Cyclic di-nucleotide compounds and methods of use
US11773132B2 (en) 2017-08-30 2023-10-03 Beijing Xuanyi Pharmasciences Co., Ltd. Cyclic di-nucleotides as stimulator of interferon genes modulators
WO2019043634A2 (en) 2017-08-30 2019-03-07 Beijing Xuanyi Pharmasciences Co., Ltd. CYCLIC DI-NUCLEOTIDES AS STIMULATORS OF INTERFERON GENE MODULATORS
US11787833B2 (en) 2019-05-09 2023-10-17 Aligos Therapeutics, Inc. Modified cyclic dinucleoside compounds as sting modulators

Also Published As

Publication number Publication date
US8367716B2 (en) 2013-02-05
AU2004275696A1 (en) 2005-04-07
IL173065A (en) 2011-05-31
JP2007500697A (ja) 2007-01-18
WO2005030186A3 (en) 2005-07-14
EP1651242A2 (en) 2006-05-03
AU2004275696B2 (en) 2010-02-18
CA2533873A1 (en) 2005-04-07
US20070244059A1 (en) 2007-10-18
IL173065A0 (en) 2006-06-11

Similar Documents

Publication Publication Date Title
US8367716B2 (en) Method for attentuating virulence of microbial pathogens and for inhibiting microbial biofilm formation
Langendonk et al. The building blocks of antimicrobial resistance in Pseudomonas aeruginosa: implications for current resistance-breaking therapies
Mitchell et al. Staphylococcus aureus sigma B-dependent emergence of small-colony variants and biofilm production following exposure to Pseudomonas aeruginosa 4-hydroxy-2-heptylquinoline-N-oxide
Fernández et al. Creeping baselines and adaptive resistance to antibiotics
Van Laar et al. Sublethal concentrations of carbapenems alter cell morphology and genomic expression of Klebsiella pneumoniae biofilms
Arias et al. The rise of the Enterococcus: beyond vancomycin resistance
Kim et al. Guanosine tetra-and pentaphosphate increase antibiotic tolerance by reducing reactive oxygen species production in Vibrio cholerae
Espinel et al. Multiple roles of putrescine and spermidine in stress resistance and virulence of Salmonella enterica serovar Typhimurium
Martinez Mechanisms of action and of resistance to quinolones
Lahiri et al. Biofilm and antimicrobial resistance
Mechesso et al. Tylosin exposure reduces the susceptibility of Salmonella Typhimurium to florfenicol and tetracycline
Hemlata et al. The ever changing face of antibiotic resistance: Prevailing problems and preventive measures
Jolivet‐Gougeon et al. Bacterial Persistence in Biofilms and Antibiotics: Mechanisms Involved
Wagley et al. A proteasome inhibitor produced by Burkholderia pseudomallei modulates intracellular growth
Trigui et al. Phenotypic and transcriptomic responses of Campylobacter jejuni suspended in an artificial freshwater medium
Ravishankar Investigation of antibiofilm and antivirulence activity of 5-fluorocytosine in Escherichia coli
Gómez et al. Transcriptomic analysis of sub-MIC Eugenol exposition on antibiotic resistance profile in Multidrug Resistant Enterococcus faecalis E9. 8
Rothstein et al. Rifalazil retains activity against rifampin-resistant mutants of Chlamydia pneumoniae
Elkrewi Investigating the prevalence and genetic basis of resistance to the antimicrobial agents bacitracin, nitrofurantoin and silver in key pathogenic bacteria
Reynolds Cyclic di-GMP Regulates Motility, Biofilm Formation, and Desiccation Tolerance in Acinetobacter baumannii
Kar et al. Quorum sensing mediated attenuation of biofilm formation and virulence traits in Staphylococcus aureus by trigonelline
Ih Mechanisms and PK/PD modelling of MCR-1-induced adaptive resistance in Enterobacteriaceae
Scoffone et al. Antimicrobial drug efflux pumps in Burkholderia
Plume Characterising a novel heavy metal-sensing multikinase network in the environmental organism and opportunistic pathogen, Burkholderia cenocepacia
Alrahmany et al. Molecular Basis of Resistance II

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2533873

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006521912

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004275696

Country of ref document: AU

Ref document number: 2004809506

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2004275696

Country of ref document: AU

Date of ref document: 20040722

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004809506

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10565591

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10565591

Country of ref document: US